Intra-Cellular Reports the Expansion of Pipeline with the Addition of ITI-1284

February 25, 2021 Auto Bot Expansion, Pharma, Pipeline, reports 0

Shots:

  • Following the completion of a P-I program, the company plans to initiate P- II studies to evaluate ITI-1284 ODT-SL for the treatment of behavioral disturbances in dementia, dementia-related psychosis and certain depressive disorders in the elderly
  • The P-I single and multiple ascending dose studies in healthy volunteers including elderly subjects aged >65yrs. evaluated the safety, tolerability and PK of ITI-1284 and reported no SAEs in either age group
  • TI-1284 is a deuterated form of lumateperone, delivered sublingually as an ODT-SL and offer pharmacologic benefits and ease of use for patients, particularly in elderly populations

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: The Science of Parkinson’s

The post Intra-Cellular Reports the Expansion of Pipeline with the Addition of ITI-1284 first appeared on PharmaShots.